Growth Drivers GSK is experiencing growth in specialty medicines and is actively working to accelerate its pipeline ahead of an HIV patent cliff, presenting opportunities to engage in partnerships, licensing, or co-development discussions to complement its oncology and infectious disease portfolios.

Vaccine & mRNA Recent data comparing GSK's mRNA flu vaccine to Moderna suggests potential collaboration or licensing opportunities in mRNA vaccine platforms, cold chain optimization, and large-scale manufacturing partnerships.

Strategic Partnerships GSK has active licensing deals with external biotech (eg Hutchmed) for KRAS-EGFR therapies, indicating openness to outside-in collaborations for late-stage assets, manufacturing support, and regional commercialization rights outside core markets.

Analytics-Driven GSK's tech stack includes IBM Cognos, Hyperion, IBM SPSS, and analytics tools, signaling a potential need for advanced data services, reporting automation, forecasting optimization, and AI-enabled trial analytics to improve R&D or commercial operations.

Global Scale With over 10,000 employees and revenue exceeding $10B, GSK represents a large enterprise customer likely to seek enterprise-grade solutions in areas such as supply chain visibility, ERP/financial planning, and commercial analytics to support global operations.